Clinical Trial

Adrenergic Antibodies in Postural Tachycardia Syndrome

Study Description

POTS Adrenergic Ab (CIHR Aims #1&2)

Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Phenylephrine

incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg

Drug - Isoproterenol

incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm

Additional Information

Official Study Title

The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)

Clinical Trial ID

NCT02673996

ParticipAid ID

7e5KXb